カテゴリー： QYResearch, 世界, 医療/バイオ

心臓刺激剤のグローバル市場2023年：強心配糖体、非強心配糖体

◆英語タイトル：Global Cardiac Stimulant Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8713）◆商品コード：QYR23MA8713
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：95
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の心臓刺激剤市場について調査・分析し、世界の心臓刺激剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（強心配糖体、非強心配糖体）、用途別セグメント分析（病院、診療所）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Teva Pharmaceutical Industries Ltd.、Novartis、Pfizer、Sanofi、Sigma-Aldrich、Johnson & Johnson、Hikma Pharmaceuticals、Baxter Healthcare、Teligent、Amneal Pharmaceuticals, Inc.、Sterimax、AVKARE、Marlex Pharmaceuticalsなどが含まれています。世界の心臓刺激剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、心臓刺激剤市場規模を推定する際に考慮しました。

・心臓刺激剤市場の概要
- 製品の定義
- 心臓刺激剤のタイプ別セグメント
- 世界の心臓刺激剤市場規模：タイプ別分析（強心配糖体、非強心配糖体）
- 心臓刺激剤の用途別セグメント
- 世界の心臓刺激剤市場規模：用途別分析（病院、診療所）
- 世界の心臓刺激剤市場規模予測（2018年-2029年）
- 心臓刺激剤の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 心臓刺激剤市場の競争状況およびトレンド

・心臓刺激剤の地域別市場規模
- 北米の心臓刺激剤市場規模（2018年-2029年）
- アメリカの心臓刺激剤市場規模（2018年-2029年）
- ヨーロッパの心臓刺激剤市場規模（2018年-2029年）
- アジア太平洋の心臓刺激剤市場規模（2018年-2029年）
- 中国の心臓刺激剤市場規模（2018年-2029年）
- 日本の心臓刺激剤市場規模（2018年-2029年）
- 韓国の心臓刺激剤市場規模（2018年-2029年）
- インドの心臓刺激剤市場規模（2018年-2029年）
- オーストラリアの心臓刺激剤市場規模（2018年-2029年）
- 中南米の心臓刺激剤市場規模（2018年-2029年）
- 中東・アフリカの心臓刺激剤市場規模（2018年-2029年）

・タイプ別セグメント：強心配糖体、非強心配糖体
- 世界の心臓刺激剤のタイプ別販売量（2018年-2023年）
- 世界の心臓刺激剤のタイプ別売上（2018年-2023年）
- 世界の心臓刺激剤のタイプ別価格

・用途別セグメント：病院、診療所
- 世界の心臓刺激剤の用途別販売量（2018年-2023年）
- 世界の心臓刺激剤の用途別売上（2018年-2023年）
- 世界の心臓刺激剤の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Teva Pharmaceutical Industries Ltd.、Novartis、Pfizer、Sanofi、Sigma-Aldrich、Johnson & Johnson、Hikma Pharmaceuticals、Baxter Healthcare、Teligent、Amneal Pharmaceuticals, Inc.、Sterimax、AVKARE、Marlex Pharmaceuticals

・産業チェーンと販売チャネルの分析
- 心臓刺激剤産業チェーン分析
- 心臓刺激剤の主要原材料
- 心臓刺激剤の販売チャネル
- 心臓刺激剤のディストリビューター
- 心臓刺激剤の主要顧客

・心臓刺激剤市場ダイナミクス
- 心臓刺激剤の業界動向
- 心臓刺激剤市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Cardiac Stimulant market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cardiac Stimulant is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cardiac Stimulant is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cardiac Stimulant include Teva Pharmaceutical Industries Ltd., Novartis, Pfizer, Sanofi, Sigma-Aldrich, Johnson & Johnson, Hikma Pharmaceuticals, Baxter Healthcare and Teligent, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cardiac Stimulant, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiac Stimulant.
The Cardiac Stimulant market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiac Stimulant market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiac Stimulant manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Teva Pharmaceutical Industries Ltd.
Novartis
Pfizer
Sanofi
Sigma-Aldrich
Johnson & Johnson
Hikma Pharmaceuticals
Baxter Healthcare
Teligent
Amneal Pharmaceuticals, Inc.
Sterimax
AVKARE
Marlex Pharmaceuticals
Segment by Type
Cardiac Glycosides
Non-Cardiac Glycosides
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cardiac Stimulant manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cardiac Stimulant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Cardiac Stimulant Market Overview
1.1 Product Overview and Scope of Cardiac Stimulant
1.2 Cardiac Stimulant Segment by Type
1.2.1 Global Cardiac Stimulant Market Value Comparison by Type (2023-2029)
1.2.2 Cardiac Glycosides
1.2.3 Non-Cardiac Glycosides
1.3 Cardiac Stimulant Segment by Application
1.3.1 Global Cardiac Stimulant Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Cardiac Stimulant Market Size Estimates and Forecasts
1.4.1 Global Cardiac Stimulant Revenue 2018-2029
1.4.2 Global Cardiac Stimulant Sales 2018-2029
1.4.3 Global Cardiac Stimulant Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cardiac Stimulant Market Competition by Manufacturers
2.1 Global Cardiac Stimulant Sales Market Share by Manufacturers (2018-2023)
2.2 Global Cardiac Stimulant Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Cardiac Stimulant Average Price by Manufacturers (2018-2023)
2.4 Global Cardiac Stimulant Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cardiac Stimulant, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cardiac Stimulant, Product Type & Application
2.7 Cardiac Stimulant Market Competitive Situation and Trends
2.7.1 Cardiac Stimulant Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cardiac Stimulant Players Market Share by Revenue
2.7.3 Global Cardiac Stimulant Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cardiac Stimulant Retrospective Market Scenario by Region
3.1 Global Cardiac Stimulant Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cardiac Stimulant Global Cardiac Stimulant Sales by Region: 2018-2029
3.2.1 Global Cardiac Stimulant Sales by Region: 2018-2023
3.2.2 Global Cardiac Stimulant Sales by Region: 2024-2029
3.3 Global Cardiac Stimulant Global Cardiac Stimulant Revenue by Region: 2018-2029
3.3.1 Global Cardiac Stimulant Revenue by Region: 2018-2023
3.3.2 Global Cardiac Stimulant Revenue by Region: 2024-2029
3.4 North America Cardiac Stimulant Market Facts & Figures by Country
3.4.1 North America Cardiac Stimulant Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cardiac Stimulant Sales by Country (2018-2029)
3.4.3 North America Cardiac Stimulant Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cardiac Stimulant Market Facts & Figures by Country
3.5.1 Europe Cardiac Stimulant Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cardiac Stimulant Sales by Country (2018-2029)
3.5.3 Europe Cardiac Stimulant Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cardiac Stimulant Market Facts & Figures by Country
3.6.1 Asia Pacific Cardiac Stimulant Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cardiac Stimulant Sales by Country (2018-2029)
3.6.3 Asia Pacific Cardiac Stimulant Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cardiac Stimulant Market Facts & Figures by Country
3.7.1 Latin America Cardiac Stimulant Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cardiac Stimulant Sales by Country (2018-2029)
3.7.3 Latin America Cardiac Stimulant Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cardiac Stimulant Market Facts & Figures by Country
3.8.1 Middle East and Africa Cardiac Stimulant Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cardiac Stimulant Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cardiac Stimulant Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cardiac Stimulant Sales by Type (2018-2029)
4.1.1 Global Cardiac Stimulant Sales by Type (2018-2023)
4.1.2 Global Cardiac Stimulant Sales by Type (2024-2029)
4.1.3 Global Cardiac Stimulant Sales Market Share by Type (2018-2029)
4.2 Global Cardiac Stimulant Revenue by Type (2018-2029)
4.2.1 Global Cardiac Stimulant Revenue by Type (2018-2023)
4.2.2 Global Cardiac Stimulant Revenue by Type (2024-2029)
4.2.3 Global Cardiac Stimulant Revenue Market Share by Type (2018-2029)
4.3 Global Cardiac Stimulant Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cardiac Stimulant Sales by Application (2018-2029)
5.1.1 Global Cardiac Stimulant Sales by Application (2018-2023)
5.1.2 Global Cardiac Stimulant Sales by Application (2024-2029)
5.1.3 Global Cardiac Stimulant Sales Market Share by Application (2018-2029)
5.2 Global Cardiac Stimulant Revenue by Application (2018-2029)
5.2.1 Global Cardiac Stimulant Revenue by Application (2018-2023)
5.2.2 Global Cardiac Stimulant Revenue by Application (2024-2029)
5.2.3 Global Cardiac Stimulant Revenue Market Share by Application (2018-2029)
5.3 Global Cardiac Stimulant Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Teva Pharmaceutical Industries Ltd.
6.1.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.1.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.1.3 Teva Pharmaceutical Industries Ltd. Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Teva Pharmaceutical Industries Ltd. Cardiac Stimulant Product Portfolio
6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Cardiac Stimulant Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Cardiac Stimulant Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Cardiac Stimulant Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Sigma-Aldrich
6.5.1 Sigma-Aldrich Corporation Information
6.5.2 Sigma-Aldrich Description and Business Overview
6.5.3 Sigma-Aldrich Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sigma-Aldrich Cardiac Stimulant Product Portfolio
6.5.5 Sigma-Aldrich Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Johnson & Johnson Cardiac Stimulant Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Hikma Pharmaceuticals
6.6.1 Hikma Pharmaceuticals Corporation Information
6.6.2 Hikma Pharmaceuticals Description and Business Overview
6.6.3 Hikma Pharmaceuticals Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hikma Pharmaceuticals Cardiac Stimulant Product Portfolio
6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
6.8 Baxter Healthcare
6.8.1 Baxter Healthcare Corporation Information
6.8.2 Baxter Healthcare Description and Business Overview
6.8.3 Baxter Healthcare Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Baxter Healthcare Cardiac Stimulant Product Portfolio
6.8.5 Baxter Healthcare Recent Developments/Updates
6.9 Teligent
6.9.1 Teligent Corporation Information
6.9.2 Teligent Description and Business Overview
6.9.3 Teligent Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Teligent Cardiac Stimulant Product Portfolio
6.9.5 Teligent Recent Developments/Updates
6.10 Amneal Pharmaceuticals, Inc.
6.10.1 Amneal Pharmaceuticals, Inc. Corporation Information
6.10.2 Amneal Pharmaceuticals, Inc. Description and Business Overview
6.10.3 Amneal Pharmaceuticals, Inc. Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Amneal Pharmaceuticals, Inc. Cardiac Stimulant Product Portfolio
6.10.5 Amneal Pharmaceuticals, Inc. Recent Developments/Updates
6.11 Sterimax
6.11.1 Sterimax Corporation Information
6.11.2 Sterimax Cardiac Stimulant Description and Business Overview
6.11.3 Sterimax Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Sterimax Cardiac Stimulant Product Portfolio
6.11.5 Sterimax Recent Developments/Updates
6.12 AVKARE
6.12.1 AVKARE Corporation Information
6.12.2 AVKARE Cardiac Stimulant Description and Business Overview
6.12.3 AVKARE Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.12.4 AVKARE Cardiac Stimulant Product Portfolio
6.12.5 AVKARE Recent Developments/Updates
6.13 Marlex Pharmaceuticals
6.13.1 Marlex Pharmaceuticals Corporation Information
6.13.2 Marlex Pharmaceuticals Cardiac Stimulant Description and Business Overview
6.13.3 Marlex Pharmaceuticals Cardiac Stimulant Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Marlex Pharmaceuticals Cardiac Stimulant Product Portfolio
6.13.5 Marlex Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cardiac Stimulant Industry Chain Analysis
7.2 Cardiac Stimulant Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cardiac Stimulant Production Mode & Process
7.4 Cardiac Stimulant Sales and Marketing
7.4.1 Cardiac Stimulant Sales Channels
7.4.2 Cardiac Stimulant Distributors
7.5 Cardiac Stimulant Customers
8 Cardiac Stimulant Market Dynamics
8.1 Cardiac Stimulant Industry Trends
8.2 Cardiac Stimulant Market Drivers
8.3 Cardiac Stimulant Market Challenges
8.4 Cardiac Stimulant Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 心臓刺激剤のグローバル市場2023年：強心配糖体、非強心配糖体(Global Cardiac Stimulant Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 刺激物無添加プレワークアウトサプリメントの世界市場見通し2023年-2029年
  • 不整脈治療のグローバル市場2023年：ナトリウムチャネル遮断薬、ベータ遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬、その他
  • 心臓外科用パッチのグローバル市場展望 2023年-2029年：バイオフィルム、高分子合成膜

    • ◆H&Iグローバルリサーチのお客様（例）◆